This month, we want to share the acknowledgment that APICES has received in the recent publication titled “Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study”, published…
This month, we want to share the acknowledgment that APICES has received in the recent publication of COMISH study titled: “Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in…
This month, we want to share the acknowledgment that APICES has received in the recent publication titled “A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the Geminis study”
Amelia Martín Uranga, Associate Director of Clinical and Translational Research at Farmaindustria, explains why Spain is an international leader in clinical trials. Spain is the second country in terms of investment by the pharmaceutical industry, behind the United…
APICES corporate video is available on the Clinical Trials Arena website Hi everybody, APICES corporate video is now also available on the Clinical Trials Arena website. Enjoy it! https://www.clinicaltrialsarena.com/contractors/clinical-trials/apices/#apices (select tab “videos”)
Spanish CRO APICES boosts its expansion and growth plans with the integration of the French CRO Kappa Santé. With this operation, the Spanish company will have offices in Paris (France), consolidating its growth and fostering collaboration with other research…
This month, we want to share the acknowledgment that APICES has received in the recent publication titled “A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the Geminis study”
We want to share the acknowledgment that APICES has received in the recent publication titled “Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian…
